In the realm of pharmaceutical development, the selection of excipients and advanced intermediates is critical for ensuring the efficacy, safety, and manufacturability of drug products. Piroxicambeta-Cyclodextrin, identified by CAS number 121696-62-6, stands out as a valuable compound that addresses several formulation challenges, particularly for NSAIDs like Piroxicam.

Piroxicambeta-Cyclodextrin is essentially a complex formed between Piroxicam, a well-known NSAID, and beta-cyclodextrin. This complexation process is designed to leverage the unique properties of beta-cyclodextrins to improve the characteristics of Piroxicam. The primary goal is to enhance its solubility in aqueous environments, which is often a limiting factor for oral drug absorption. By improving solubility, the complex facilitates faster dissolution in the gastrointestinal tract, leading to more efficient absorption and a potentially quicker therapeutic response.

Beyond solubility enhancement, Piroxicam-Beta-Cyclodextrin also plays a crucial role in mitigating the adverse effects often associated with Piroxicam. One of the significant drawbacks of conventional Piroxicam is its potential to cause gastrointestinal irritation and damage. The formation of the cyclodextrin inclusion complex helps to shield the drug from direct contact with the stomach lining, thereby reducing local toxicity and improving gastrointestinal tolerability. This makes it a more patient-friendly option for chronic or long-term use.

For pharmaceutical manufacturers and researchers, sourcing this intermediate requires attention to quality and reliability. High-purity Piroxicambeta-Cyclodextrin, typically with an assay of 99.5% or higher, is essential for consistent drug product performance. Companies looking to procure this material often seek out established manufacturers and suppliers that can guarantee product quality and provide necessary documentation. Understanding the various applications, from anti-inflammatory treatments to pain management formulations, guides the selection process for this vital pharmaceutical intermediate.